{"brief_title": "Prevention Of Recurrence Of Atrial Fibrillation", "brief_summary": "The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).", "condition": ["Fibrillation, Atrial"], "intervention_type": ["Drug", "Other"], "intervention_name": ["SB-207266", "Placebo"], "description": ["White, oval, biconvex tablets containing either 10mg, 25mg or 40mg", "Placebo to match SB-207266"], "arm_group_label": ["Arm 1", "Arm 2"], "criteria": "Inclusion Criteria: - Symptomatic persistent atrial fibrillation requiring DC cardioversion. - Duration of AF >48 hrs. <6 months Exclusion Criteria: - Concomitant Class I and/or III anti-arrhythmic drugs. - Amiodarone treatment within 3 months of the study. - Other inclusion or exclusion criteria to be determined by the physician and study sponsor.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "persistent atrial fibrillation", "mesh_term": ["Atrial Fibrillation"], "id": "NCT00041496"}